Federal Circuit vacates injunction in Amgen’s dispute with Sanofi
11 October 2017
|
Michael Loney, New York
The permanent injunction granted by the District of Delaware in the dispute between Amgen and Sanofi/Regeneron over cholesterol-lowering treatment has been vacated, in a decision that also included some implications for the USPTO’s practice of granting broad antibody claims
The Federal Circuit has vacated the permanent injunction in
the dispute between Amgen and Sanofi/Regeneron over
cholesterol-lowering treatment.
Sanofi and Regeneron Pharmaceuticals appealed a final
judgment of the District of Delaware in January that held that
two patents were...
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here